Compare Adaptive Biotechnologies Corp (ADPT) vs Fiverr International Ltd (FVRR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Fiverr International Ltd — how do they compare? Adaptive Biotechnologies Corp trades at $25.31 (market cap $4.04B), while Fiverr International Ltd trades at $8.78 (market cap $314.57M). The key difference: Adaptive Biotechnologies Corp is far larger — about 12.8× Fiverr International Ltd's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Fiverr International Ltd nearer its low. Which is the better fit depends on your goals.
| ADPT | FVRR | |
|---|---|---|
Market Cap | $4.04B | $314.57M |
Sector | Health | Industrials |
52-Week High | $25.45 | $26.67 |
52-Week Low | $12.30 | $8.66 |
Enterprise Value | $4.10B | $66.95M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.
The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.
Fiverr International (FVRR) trades at $8.66, down 4.73% amid bearish technical signals and recent earnings misses. The stock shows attractive valuation ratios with a P/E of 10.8 and P/S of 0.77, but faces headwinds from AI disruption compressing demand for freelance services. Revenue declined to $97.8 million in Q2 2026 (MarketBeat, July 29, 2026), contributing to a lowered full-year outlook.
The investment outlook is cautious. While valuations appear cheap and the company maintains a strong gross margin of 82%, significant risks from competitive AI technologies and recent execution challenges temper near-term optimism. Analyst consensus leans Hold with a $10.70 price target, suggesting limited upside from current levels amid transitional pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →
